Posted: 27 June 2024
INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease.
NEURO-NET captures exosomes secreted from various brain cells. Exosomes provide a “fingerprint” of the health or disease status of the parent cell and can cross the “blood-brain barrier”, making them promising candidates as diagnostics for neurological diseases. The ability to weaponize exosomes and target them to cells is the end game for therapy and cure.
Initial analytical and clinical validation studies showed:
- Exosomes isolated from blood using NEURO-NET contain proteins known to be expressed by brain cells;
- NEURO-NET was superior to other commercially-available methods tested in isolating brainderived exosomes from blood;
- NEURO-NET enabled the identification of known Alzheimer’s biomarkers in exosomes that could not be detected by other methods;
- Analysis of NEURO-NET-captured exosomes identified more than 200 proteins that were differentially expressed in Alzheimer’s patients when compared with healthy individuals.
These results were further validated by a larger independent study (48 cases and 44 controls) conducted by the Walter & Elisa Hall Institute, confirming the differential expression of previously identified proteins. Importantly, 47 proteins were uniquely expressed in exosomes isolated from Alzheimer’s blood samples and provided robust discrimination between cases and controls.
CEO Leearne Hinch said: “INOVIQ’s NEURO-NET product is an important addition to our exosome portfolio. These results validate the ability of NEURO-NET to isolate exosomes from the brain and provide INOVIQ with opportunities to collaborate with pharma, diagnostic companies and leading academic groups to develop and validate new diagnostic tests using novel and informative biomarkers for brain cancer, neuropsychiatric disorders and neurodegenerative diseases.”
Chairman David Williams said: “NEURO-NET expands INOVIQ’s platform exosome capabilities to develop new diagnostics for neurological conditions. Brain-derived exosomes hold enormous potential for the diagnosis and treatment of neurological diseases like Alzheimer’s and Parkinson’s.”
